Bengaluru: Indegene, a technology-led healthcare solutions provider, has paid $10 million for Medical Marketing Economics (MME), a company located in the United States. MME has more than 40 experts in pricing, reimbursement, and market access (PRMA) services in the healthcare industry.
“Given the pressure on medication pricing in Western nations, particularly after the financial crisis of 2007-08, when life sciences firms introduce a novel molecule, they must make a case for why that molecule should be priced at that level. Manish Gupta, co-founder and CEO of Indegene, stated, “The entire domain of medication price and market access is becoming increasingly significant for the pharma sector.”
Clinical, medical, and commercial outcomes are delivered to global healthcare organizations by the Bengaluru-based firm, which generated sales of $130 million in 2020-21. Over the last 10 years, revenue has grown at a CAGR of 25%.
“One issue on every biotech CEO’s concern,” Gupta added, “is how can I get my medications to gain the attention of the payers?” The purpose of this acquisition is to close that competence gap. That capacity existed, albeit on a very limited scale. This business is well-versed in a variety of fields, including rare illnesses and oncology.”
Indegene is putting a lot of money into new biotech companies. According to McKinsey, one out of every two blockbuster medicines (with sales of more than $1 billion) released between 2021 and 2025 will come from an emerging biotech business. Over 90% of next-generation biotherapeutics (NGB) are being developed by emerging biopharma firms, which comprise a cell, gene, and RNAi technologies, which is a biological process in which RNA molecules are engaged in particular gene expression suppression, among other things. MME has experts in this field and provides a comprehensive range of digital commercialization services.
“This relationship provides us access to a bigger client base, a worldwide operations infrastructure, and tremendous potential for development through adjacent services,” said Jack M Mycka, global president and CEO of MME. We can assist customers to discover, frame, convey, and realize the value of their medical breakthroughs in addition to Indegene’s clinical, medical, and commercial solutions.”